Optimizing COVID-19 testing resources use with wearable sensors.

Publication date: Sep 01, 2024

The timely identification of infectious pre-symptomatic and asymptomatic cases is key towards preventing the spread of a viral illness like COVID-19. Early identification has been done through routine testing programs, which are indeed costly and potentially burdensome for individuals who should be tested with high frequency. A supplemental tool is represented by wearable technology, that can passively monitor and identify individuals at high risk, alerting them to take a test. We designed a Markov chain model and simulated a routine testing and a wearable testing strategy to estimate the number of tests required and the average number of days in which an individual is infectious and undetected. According to our model, with 2 test per month available, we have that the number of infectious and undetected days is 4. 1 in the case of routine testing, while it decreases by 46% and 27% with a wearable testing strategy in the presence or absence of self-reported symptoms. The proposed parametric model can be used for different viral illnesses by tuning its parameters. It shows that wearable technology informing a testing strategy can significantly reduce the number of infectious days in which an individuals can spread the virus. With the same number of infectious days, by using wearables we can potentially reduce the number of required tests and the cost of the testing strategy.

Open Access PDF

Concepts Keywords
Covid Covid
Month Days
Symptomatic High
Viral Individuals
Infectious
Reduce
Required
Routine
Spread
Test
Testing
Tests
Undetected
Viral
Wearable

Semantics

Type Source Name
disease MESH COVID-19
disease MESH viral infections
disease MESH infection
pathway REACTOME Reproduction
disease MESH community transmission
disease IDO contact tracing
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Isoxaflutole
disease IDO process
disease IDO intervention
disease MESH privacy
disease IDO algorithm
drug DRUGBANK Saquinavir
drug DRUGBANK Flunarizine
drug DRUGBANK Cysteamine
drug DRUGBANK Parathyroid hormone
disease MESH infectious diseases
drug DRUGBANK Alprostadil

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *